Jade Biosciences Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024
Selling, General & Admin	28.07	20.42	8.61
Research & Development	136.67	93.12	55.87
Operating Expenses	164.74	113.54	64.48
Operating Income	-164.74	-113.54	-64.48
Interest Expense	-3.6	-3.6	-
Interest & Investment Income	11.67	7.78	2.32
Other Non Operating Income (Expenses)	3.52	3.59	-
EBT Excluding Unusual Items	-153.15	-105.77	-62.16
Other Unusual Items	-	-21.58	-31.8
Pretax Income	-153.15	-127.35	-93.96
Income Tax Expense	0.09	0.06	-
Net Income	-153.24	-127.41	-93.96
Preferred Dividends & Other Adjustments	-28.8	-27.27	-
Net Income to Common	-124.44	-100.14	-93.96
Net Income Growth	-	-	-
Shares Outstanding (Basic)	53	31	3
Shares Outstanding (Diluted)	53	31	3
Shares Change	-	893.82%	-
EPS (Basic)	-2.34	-3.19	-29.78
EPS (Diluted)	-2.34	-3.19	-29.78
EPS Growth	-	-	-

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024
Free Cash Flow	-123.57	-94.89	-45.23
Free Cash Flow Per Share	-2.33	-3.03	-14.33
EBITDA	-164.7	-113.52	-
D&A For EBITDA	0.04	0.03	-
EBIT	-164.74	-113.54	-64.48

SEC Filings: 10-K · 10-Q